Shares of Gilead Sciences have advanced more than 10% this Friday, after details of a clinical trial with the company's antiviral drug Remdesivir have been leaked, showing what they appear to be. promising results in the treatment of Covid-19.
The University of Chicago Phase 3 drug trial found that most of their patients had "rapid recoveries from fever and respiratory symptoms" and were discharged in less than a week, reported the health publication 'STAT News'.
“The best news is that most of our patients have already been discharged, which is great. Only two patients have died, "explained University of Chicago infectious disease specialist Kathleen Mullane, according to 'STAT News.' 'CNBC' also explains that the University of Chicago School of Medicine recruited 125 patients with the virus in the two clinical trials carried out, of which 113 were seriously ill. Gilead intends to enroll 4,000 people in their studies.
To date, there are no proven therapies to treat Covid-19, which has already infected more than 2.1 million people worldwide and has killed at least 142,148, according to data compiled Thursday by Johns Hopkins University. . And given the expectations that producing a vaccine to prevent Covid-19 will take at least 12 to 18 months, find an effective drug treatment at this stage it will be crucial.
The medicine Remdesivir from Gilead Science and hydroxychloroquine, which has been used against malaria, are leading clinical trials looking for an effective treatment for coronavirus, but neither has proven effective to date. The antiviral Remdesivirde the American company has shown promise in the treatment of SARS and MERS, which are also caused by coronaviruses. Some health authorities in the US, China and other parts of the world have already been using this drug, which has been tested as a possible treatment for the Ebola outbreak, in the hope that it may reduce the duration of Covid-19 in patients.
The results of Gilead's clinical trials in severe cases of the virus are expected this month, and another trial is expected to be published in May in patients with moderate symptoms.